452 related articles for article (PubMed ID: 15734951)
41. CA54/61 as a marker for epithelial ovarian cancer.
Nozawa S; Aoki D; Yajima M; Tsukazaki K; Kobayashi T; Kimura E; Terashima Y; Inaba N; Takamizawa H; Negishi Y
Cancer Res; 1992 Mar; 52(5):1205-9. PubMed ID: 1737381
[TBL] [Abstract][Full Text] [Related]
42. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
43. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
44. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
45. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
[TBL] [Abstract][Full Text] [Related]
46. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma.
Kurihara T; Mizunuma H; Obara M; Andoh K; Ibuki Y; Nishimura T
Gynecol Oncol; 1998 Jun; 69(3):192-6. PubMed ID: 9648586
[TBL] [Abstract][Full Text] [Related]
47. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
48. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
[TBL] [Abstract][Full Text] [Related]
49. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
50. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
51. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
52. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
Inoue M; Ogawa H; Nakanishi K; Tanizawa O; Karino K; Endo J
Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
[TBL] [Abstract][Full Text] [Related]
53. Immunoassay of CA125 in ovarian cancer: a comparison of three assays for use in diagnosis and monitoring.
Fisken J; Leonard RC; Roulston JE
Dis Markers; 1989; 7(1):61-7. PubMed ID: 2653700
[TBL] [Abstract][Full Text] [Related]
54. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
[TBL] [Abstract][Full Text] [Related]
55. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma.
Jennings TS; Dottino PR; Mandeli JP; Segna RA; Kelliher K; Cohen CJ
Gynecol Oncol; 1994 Nov; 55(2):190-7. PubMed ID: 7959283
[TBL] [Abstract][Full Text] [Related]
56. [The clinical usefulness of the measurement of serum sialyl SSEA-1 antigen levels in patients with gynecologic diseases: as respects the comparative effectiveness of sialyl SSEA-1 and CA125].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Jul; 40(7):828-34. PubMed ID: 3166483
[TBL] [Abstract][Full Text] [Related]
57. CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.
Ismail MA; Rotmensch J; Mercer LJ; Block BS; Salti GI; Holt JA
J Reprod Med; 1994 Jul; 39(7):510-2. PubMed ID: 7966039
[TBL] [Abstract][Full Text] [Related]
58. CA125 based diagnosis and therapy in recurrent ovarian cancer.
Meier W; Baumgartner L; Stieber P; Hasholzner U; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3019-20. PubMed ID: 9329590
[TBL] [Abstract][Full Text] [Related]
59. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
[TBL] [Abstract][Full Text] [Related]
60. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]